Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Invested Capital: 2016-2025

Historic Invested Capital for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $339.4 million.

  • Collegium Pharmaceutical's Invested Capital rose 13.56% to $339.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.4 million, marking a year-over-year increase of 13.56%. This contributed to the annual value of $293.4 million for FY2024, which is 22.53% down from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Invested Capital is $339.4 million, which was up 14.35% from $296.8 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Invested Capital's 5-year high stood at $846.1 million during Q1 2022, with a 5-year trough of $293.4 million in Q4 2024.
  • Its 3-year average for Invested Capital is $409.9 million, with a median of $362.2 million in 2023.
  • In the last 5 years, Collegium Pharmaceutical's Invested Capital spiked by 164.37% in 2022 and then slumped by 54.56% in 2023.
  • Quarterly analysis of 5 years shows Collegium Pharmaceutical's Invested Capital stood at $346.7 million in 2021, then skyrocketed by 122.06% to $769.8 million in 2022, then slumped by 50.80% to $378.8 million in 2023, then declined by 22.53% to $293.4 million in 2024, then rose by 13.56% to $339.4 million in 2025.
  • Its Invested Capital was $339.4 million in Q3 2025, compared to $296.8 million in Q2 2025 and $299.0 million in Q1 2025.